argenx SE

... ...
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
VRXValeant Pharmaceuticals International, Inc. -0.78%26.7914.1%$157.64m
HZNPHorizon Therapeutics Plc -3.54%75.745.6%$141.54m
ACRSAclaris Therapeutics, Inc. 0.23%17.684.7%$136.27m
BHCBausch Health Cos., Inc. -0.78%26.790.0%$108.62m
CTLTCatalent, Inc. -1.07%114.492.1%$105.68m
JAZZJazz Pharmaceuticals Plc -2.19%167.242.4%$88.99m
AMRNAmarin Corp. Plc -0.62%7.511.5%$62.52m
UTHRUnited Therapeutics Corp. -1.69%166.4914.1%$60.86m
ISRIsoRay, Inc. -5.00%2.092.5%$57.67m
ACSTAcasti Pharma, Inc. -2.28%0.740.2%$55.97m
PRGOPerrigo Co. Plc -0.36%44.346.8%$54.36m
GWPHGW Pharmaceuticals Plc 3.18%147.956.1%$54.26m
SAVACassava Sciences, Inc. -1.63%15.430.0%$51.79m
ARGXargenx SE -3.06%305.680.0%$51.73m
ICPTIntercept Pharmaceuticals, Inc. 1.78%33.7316.8%$43.62m

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.